Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial

J Potter,¹* A Mistri,² F Brodie,² J Chernova,² E Wilson,¹ C Jagger,² M James,³ G Ford⁴ and T Robinson²

¹University of East Anglia, UK
²University of Leicester, UK
³Royal Devon and Exeter NHS Foundation Trust, UK
⁴University of Newcastle upon Tyne, UK

*Corresponding author

Executive summary

Health Technology Assessment 2009; Vol. 13: No. 9
DOI: 10.3310/hta13090
Executive summary

**Background**

Elevated blood pressure (BP) levels are common following acute stroke and may have an adverse prognostic effect. Observational data, however, suggest that both high and low BP levels in the acute stroke period are associated with a poor short- and long-term prognosis.

The limited data available from randomised controlled trials of BP reduction following acute stroke suggest that beta-blockers and calcium channel blockers commenced within 24–48 hours of stroke onset are unlikely to have benefit in terms of reducing short- or long-term disability or death. Other trials suggest that labetalol and the angiotensin receptor blockers may be effective post stroke, with one trial showing that candesartan nearly halved the number of subsequent fatal and non-fatal vascular events in severely hypertensive, non-dysphagic, acute ischaemic stroke patients. Conversely, an induced BP increase is a standard treatment for cerebral ischaemia in patients with vasospasm after subarachnoid haemorrhage, but few data exist to support this therapy in acute ischaemic stroke.

In view of the equivocal evidence and marked variations in clinical practice, the placebo-controlled Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) pilot trial was established to assess the safety and efficacy of therapeutically reducing BP with labetalol or lisinopril (depressor arm) in patients with hypertension (systolic BP > 160 mmHg) and acute cerebral infarction or haemorrhage and of therapeutically raising BP with phenylephrine (pressor arm) in ischaemic stroke patients with ‘low’ BP.

**Objectives**

The primary outcome measure was death and dependency at 2 weeks following pressor or depressor therapy compared with placebo. The secondary objectives were: (1) to determine the safety of acute pressor or depressor therapy post stroke assessed by early neurological deterioration; (2) to assess if stroke type (ischaemic versus haemorrhagic) affected the BP changes due to depressor therapy; (3) to evaluate the BP effects of sublingual lisinopril and intravenous labetalol; (4) to study whether the effects of therapy on BP manipulation were influenced by the time to treatment; (5) to assess the short-term (2 week) cost-effectiveness of active treatment in relation to death and dependency and the medium-term (3-month) cost-effectiveness in relation to mortality.

**Methods**

Inclusion criteria included age over 18 years with a clinical diagnosis of suspected stroke and either (1) symptom onset < 36 hours and hypertension, defined as systolic BP (SBP) > 160 mmHg (depressor arm), or (2) symptom onset < 12 hours and hypotension, defined as SBP ≤ 140 mmHg (pressor arm).

Exclusion criteria included being on antihypertensive therapy on admission and having an indication for urgent BP lowering, a contraindication to trial therapy, significant co-morbidity or a life expectancy of less than or equal to 6 months. Patients who were dysphagic and on antihypertensive treatment were included after a trial protocol amendment.

SBP levels, time of stroke onset, swallowing status and functional assessments including the modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) were determined before central randomisation in a ratio of 2:1 between active treatment and placebo for the depressor arm and 1:1 between active treatment and placebo for the pressor arm. The depressor non-dysphagic patients were assigned to stepped doses of oral lisinopril 5 mg, labetalol 50 mg or matching placebo with a target SBP of 145–155 mmHg or a SBP fall of ≥ 15 mmHg, with patients receiving additional doses at 4 and 8 hours post randomisation if target BP levels were not met. The established treatment regime was continued for 14 days post randomisation. Dysphagic patients underwent a similar titrated dose regime, receiving either sublingual lisinopril 5 mg, intravenous labetalol 50 mg or matching placebo for 72 hours.
and then therapy orally if able to swallow or via a nasogastric tube if not until day 14.

Hypotensive (SBP < 140 mmHg) patients recruited within 12 hours of ischaemic stroke and who were euvolaemic could be randomised to normal saline infusion and either intravenous phenylephrine or matching placebo, to be continued up to 24 hours after stroke onset, after which normal BP management was allowed.

At 72 hours the NIHSS was repeated to assess early stroke deterioration and at day 14 functional assessments including mRS and NIHSS were measured again. At 3 months the cause and date of death, length of hospital stay and discharge destination were recorded by the co-ordinating centre.

The primary analysis was on an intention to treat basis, comparing the numbers of subjects who were dead or dependent (mRS > 3) at 2 weeks post randomisation. Analyses were first undertaken of active treatment compared with placebo, followed by comparisons across the three treatment groups where indicated. Logistic regression analysis was used to assess the effect of depressor or pressor treatment separately on death and dependency at 2 weeks. Repeated measures analysis of BP at baseline and at 4, 8 and 24 hours was performed using a generalised estimating equations (GEE) model. Differences in 3-month mortality and cost-effectiveness data were also assessed. Significance levels were set at 5%.

Results

A total of 180 patients were recruited over the 36-month trial period, 179 in the depressor arm and one in the pressor arm (who received placebo). Study recruitment was less than anticipated (being 11% in the depressor arm), primarily related to the number of centres enrolled and the presence of study exclusion criteria in the majority of patients screened for study eligibility. Thus, there was limited statistical power for many of the study end points. The labetalol, lisinopril and placebo depressor groups were well matched for age, baseline BP, stroke type, time to treatment, NIHSS score and prevalence of dysphagia. In the depressor group the primary outcome measure of death and dependency at 2 weeks was assessed in 172 patients (seven patients being excluded because of non-stroke diagnosis, protocol violation or withdrawal of consent) and occurred in 61% of the active depressor treatment group and 59% of the placebo group ($p = 0.82$). There was no evidence of early neurological deterioration with labetalol or lisinopril compared with placebo and study numbers were too small to detect any differences by stroke subtype. The active depressor treatment group (lisinopril and labetalol combined) had a significantly greater fall in SBP within the first 24 hours than the placebo group [21 mmHg, 95% confidence interval (CI) 17–25, vs 11 mmHg, 95% CI 5–17; $p = 0.004$ at 24 hours], although time effects of BP lowering differed between the labetalol, lisinopril and placebo groups. Sublingual lisinopril and intravenous labetalol also significantly reduced BP within the first 24 hours compared with placebo. Patients on active treatment also had a significantly greater fall in SBP at 2 weeks than patients in the placebo group (31 mmHg, 95% CI 27–36, vs 24 mmHg, 95% CI 17–30; $p = 0.045$) although there was no significant difference in fall in diastolic BP (DBP; 13 mmHg, 95% CI 8–15, vs 9 mmHg, 95% CI 5–13; $p = 0.10$).

No major safety problems were observed with labetalol or lisinopril treatment, no significant differences were seen in serious adverse events between active treatment and placebo, and no differences were found in discontinuation rates between those randomised to active treatment and those randomised to placebo. The study was too small to detect any differences in the response to hypotensive therapy between patients with cerebral infarction and those with cerebral haemorrhage. Survival analysis showed that the active treatment group had a lower mortality at 3 months ($p = 0.05$) with a hazard ratio of 2.2 (95% CI 1.0–5.0) for increased risk of death in the placebo group. Economic evaluation suggested that, on average, active treatment is both more effective and less expensive than placebo at 3 months.

Conclusion

Both labetalol and lisinopril lowered BP to a greater degree than placebo in acute stroke patients within 24 hours of symptom onset without causing serious adverse effects or an early increase in stroke severity. However, depressor therapy did not reduce death and dependency at 2 weeks, but because of the reduced numbers recruited to the trial (only 11% of the target numbers were randomised) the study was underpowered to answer this primary outcome measure. Both sublingual lisinopril and intravenous labetalol were effective hypotensive agents in the immediate post-stroke period in dysphagic patients. Of interest was
the reduction in stroke mortality at 3 months with active therapy, a finding in keeping with one other acute BP-lowering stroke trial with a 12-month follow-up period, although care must be taken in interpretation of the CHHIPS results in view of the sample size. Further work is now needed to confirm these results and to assess if there are differences in the effectiveness of labetalol compared with lisinopril in terms of reducing death or dependency after acute stroke, and whether the introduction of earlier BP lowering post stroke than was achieved in CHHIPS would be of greater benefit. That we are still uncertain as to the best management of BP in the acute stroke situation is a matter of serious concern. However, the CHHIPS pilot trial indicates that BP can be safely reduced with labetalol or lisinopril after acute stroke and that this may translate into a decrease in mortality at 3 months. These findings need to be acted on by formulating the definitive trial of BP lowering in acute stroke. The role of increasing BP in acute stroke remains unresolved, although the numbers in whom this therapy could be applied are very small based on the CHHIPS trial entry criteria.

Publication

How to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:
– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?
Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.
NIHR Health Technology Assessment Programme

The Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Second, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA Programme on behalf of NICE as project number 01/73/03. The protocol was agreed in January 2004. The assessment report began editorial review in July 2007 and was accepted for publication in June 2008. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, Dr John Powell, Dr Rob Riemisma and Professor Ken Stein